Bluejay Diagnostics (NASDAQ:BJDX) Posts Quarterly Earnings Results

Bluejay Diagnostics (NASDAQ:BJDX) announced its quarterly earnings data on Friday. The company reported ($1.01) EPS for the quarter, Zacks reports.

Bluejay Diagnostics Stock Down 1.3%

NASDAQ:BJDX traded down $0.02 during trading hours on Friday, hitting $1.57. 144,439 shares of the company were exchanged, compared to its average volume of 301,088. Bluejay Diagnostics has a one year low of $1.26 and a one year high of $10.20. The company has a fifty day simple moving average of $1.93 and a 200 day simple moving average of $1.74.

Analysts Set New Price Targets

BJDX has been the subject of several research reports. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a research report on Saturday, November 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Wednesday. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.